The effect of body mass index on therapeutic response to bacterial vaginosis in pregnancy.
Our objective was to determine the effect of body mass index (BMI) on response to bacterial vaginosis (BV) treatment. A secondary analysis was conducted of two multicenter trials of therapy for BV and TRICHOMONAS VAGINALIS. Gravida were screened for BV between 8 and 22 weeks and randomized between 16 and 23 weeks to metronidazole or placebo. Of 1497 gravida with asymptomatic BV and preconceptional BMI, 738 were randomized to metronidazole; BMI was divided into categories: < 25, 25 to 29.9, and > or = 30. Rates of BV persistence at follow-up were compared using the Mantel-Haenszel chi square. Multiple logistic regression was used to evaluate the effect of BMI on BV persistence at follow-up, adjusting for potential confounders. No association was identified between BMI and BV rate at follow-up ( P = 0.21). BMI was associated with maternal age, smoking, marital status, and black race. Compared with women with BMI of < 25, adjusted odds ratio (OR) of BV at follow-up were BMI 25 to 29.9: OR, 0.66, 95% CI 0.43 to 1.02; BMI > or = 30: OR, 0.83, 95% CI 0.54 to 1.26. We concluded that the persistence of BV after treatment was not related to BMI.
Department of Obstetrics, Gynecology and Reproductive Sciences, The University of Texas Medical School at Houston, Houston, Texas 77030, USA.
Joan M
JM
Mastrobattista
Mark A
MA
Klebanoff
J Christopher
JC
Carey
John C
JC
Hauth
Cora A
CA
Macpherson
J
J
Ernest
Margaret
M
Cotroneo
Kenneth J
KJ
Leveno
Ronald
R
Wapner
Michael
M
Varner
Jay D
JD
Iams
Atef
A
Moawad
Baha M
BM
Sibai
Menachem
M
Miodovnik
Mitchell
M
Dombrowski
Mary J
MJ
O'Sullivan
J Peter
JP
Vandorsten
Oded
O
Langer
D000328:Adult; D000981:Antiprotozoal Agents / Q000627:therapeutic use; D015992:Body Mass Index; D005260:Female; D006801:Humans; D008795:Metronidazole / Q000627:therapeutic use; D009767:Obesity, Morbid / Q000150:complications; D050177:Overweight / Q000150:complications; D011247:Pregnancy; D011248:Pregnancy Complications; D011251:Pregnancy Complications, Infectious / Q000188:drug therapy*; D016032:Randomized Controlled Trials as Topic; D016896:Treatment Outcome; D014247:Trichomonas Vaginitis / Q000188:drug therapy*
D000981:Antiprotozoal Agents; D008795:Metronidazole